True Wealth Design’s ALX Oncology ALXO Stock Holding History

True Wealth Design’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15	Closed	-$7	–	2722
2025 Q2	$7	Buy	+15	New	+$8	﹤0.01%	2551

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

True Wealth Design's ALXO Position: Q3 2025 in Review

True Wealth Design sold out of ALX Oncology (ALXO) in Q3 2025, closing a stake of 15 shares — an estimated $7 sold.

True Wealth Design first reported a position in ALXO in Q2 2025 and held it in 1 quarter. The position peaked at $7 in Q2 2025. 61 funds tracked by Wall St. Rank hold ALXO as of Q3 2025.

True Wealth Design reported no remaining ALX Oncology position as of Q3 2025 after selling out during the quarter.
True Wealth Design sold 15 ALX Oncology shares in Q3 2025, an estimated $7.
True Wealth Design first reported a position in ALX Oncology in Q2 2025 and held it in 1 quarter.
True Wealth Design's ALX Oncology position peaked at $7 in Q2 2025.
61 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2025.

Based on True Wealth Design's 13F filing for Q3 2025, filed 21 Oct 2025.